Method for hypoestrogen-induced endothelial dysfunction correction with mixed solutions of homoeopathic dilutions of polyclonal rabbit c12, c30, c200 antibodies to human endothelial nitrogen oxide synthase

FIELD: medicine.

SUBSTANCE: for the purpose of hypoestrogen-induced endothelial dysfunction correction in white female Wistar rats, hypoestrogen-induced endothelial dysfunction is simulated by bilateral ovariectomy. The dysfunction correction is ensured by introduction of mixed solutions of homoeopathic dilutions of polyclonal rabbit C12, C30, C200 antibodies to human endothelial nitrogen oxide synthase for 6 weeks following the ovariectomy. The specified mixture is added to drinking bowls once a day.

EFFECT: method provides effective correction with reducing an endothelial dysfunction coefficient in females to the level observed in intact animals ensured by the effect on various developmental mechanisms of this dysfunction in hypooestrogenic conditions.

2 tbl, 1 ex

 

The invention relates to medicine, in particular to the experimental cardiovascolari.

Closest to the claimed solution is a way of correcting hypoestrogen-induced endothelial dysfunction furostanol glycosides from cell culture plants of dioscorea deltoidea described 27.07.2008, RF patent No. 2329807.

The main disadvantage of this method is that the correction hypoestrogenemia endothelial disfuncio associated with estrogen-like activity furostanol glycosides. Therefore, the results of the correction of endothelial dysfunction in case of damage in the system L-arginine-NO, which is mainly caused by deficiency of endothelial NO-synthase, using furostanol glycosides from cell culture plants of dioscorea deltoidea with estrogen-like activity, unsatisfactory.

While the main mechanism of action of the mixture of solutions gomeopaticheskih dilutions of polyclonal rabbit antibodies to endothelial synthase nitric oxide - C12, C30, C200 is an increase of eNOS, thereby affecting the main link of pathogenesis of endothelial dysfunction, leading to increased levels of nitric oxide in the vascular trunk line and correction of endothelial dysfunction.

Object of the invention is a method for correcting hypoestrogen-induce vannoy endothelial dysfunction, including the use of a mixture of solutions gomeopaticheskih dilutions of polyclonal rabbit antibodies to endothelial synthase nitric oxide - C12, C30, C200, leading to increased levels of eNOS.

This object is achieved in that the background modeling of endothelial dysfunction in the experiment with bilateral oophorectomy in laboratory animals is its correction within 6 weeks of daily introduction of the mixture of solutions gomeopaticheskih dilutions of polyclonal rabbit antibodies to endothelial synthase nitric oxide person - C12, C30, C200 adding to drinkers in quantities taken in homeopathy, with free access to drinking, replacement of water in the drinkers were performed 1 time per day with a quantitative accounting of fluid you drink (20±3 ml on average per animal).

The METHOD IS AS follows

The experiments were carried out on white rats female Wistar weighing 200-300 g For modeling hypoestrogen-induced endothelial dysfunction in rats was narcoticyou atenalol sodium (50 mg/kg) and had a bilateral oophorectomy. On day 42 from the beginning of the experiment under anesthesia (eleminal-sodium 50 mg/kg) catheter in the left carotid artery for recording blood pressure (BP), a bolus of pharmacological agents in the right femoral ve is at. Hemodynamic parameters: systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) was measured continuously by a sensor TSD104A and hardware-software complex MP100, production Biopac System, Inc., USA. Functional tests: endothelium-dependent vasodilatation (ESV) - intravenous administration of acetyl-choline (ACH) at a dose of 40 mcg/kg, endothelium-independent vasodilatation (ANSW) - intravenous sodium nitroprusside (NP) at a dose of 30 µg/kg

When the statistical processing of the data was calculated the mean value, the standard deviation value. The differences were considered significant at p<0,05.

AN EXAMPLE OF A SPECIFIC IMPLEMENTATION.

Bolus intravenous AH within 3-5 seconds led to a sharp drop in blood pressure reaching a peak in the intact animals for systolic blood pressure (SBP) of 83.9±4.8 mm Hg for diastolic blood pressure (DBP) - 41,9±2.2 mm Hg and mean arterial pressure (Srad) 55,8±2.2 mm Hg, while during the first 2-3 sec developed sudden bradycardia up to 130-150 beats per minute (table 1).

Restoring the HELL happened in average 43,6±2,2 seconds after normalization of heart rate. This integral we have taken as the vascular component of the reaction on the AH and was used for further calculations (table 2). ANSW also what was harakterizovali decrease in the GARDEN to 91,0±4,6, Dad to 48.5±2.9 and Srad to 62.7±3.2 mm Hg (table 1) followed by complete recovery within average 40,2±2,4 sec (table 2).

Hypoestrogenemia the state, within 6 weeks after oophorectomy, called arterial hypertension (GARDEN - 160,0±6,2, dad was 124.9±5,5, Srad - 136,6±5.6 mm Hg) and lead to a smaller decline in HELL after the introduction of AH (GARDEN up to 91.8±8,0, dad to 57.3±7,1, Srad to 68.8±7,3 mm Hg) and NP (the GARDEN to 87,4±7,5, dad to 57.8±6.6 and Srad to 67,7±6.1 mm Hg) compared with intact animals (table 1).

6 weeks after the females of Wistar rats with bilateral oophorectomy was a significant decrease of the integral (response and recovery actions after the introduction of the AH) to 1022,5±131 used compared with the intact group of animals, in which the figure was 1673,6±132,4 used (table 1). On the contrary, ENSR, reflecting the response to the introduction of the NP increased in animals with experimental endothelial dysfunction and its integral, respectively 2157,3±167 used and 1338,1±121, 1million used in the control group.

A fundamental difference in ASW and ANSW in the intact animals and animals with hypoestrogenism condition naturally led us to launch a special indicator - the ratio of endothelial dysfunction (QED), which describes the degree of endothelial dysfunction, which is the ratio PLO is ADI triangle above the trend of the reduction reaction of blood pressure in response to the introduction of the NP to the area of the triangle above randomreal restore blood pressure in response to the introduction of AH.

Table 1
Dynamics of blood pressure and heart rate when modeling hypoestrogen-induced deficiency of nitric oxide and its correction with a mixture of solutions gomeopaticheskih dilutions of polyclonal rabbit antibodies to endothelial synthase nitric oxide - C12, C30, C200.
Groups of animalsFunctional testsGARDEN, mm HgDBP, mm HgHeart rate, beats per min
The intactSource128,1±6,095,7±4401,0±8,0
OH83,9±4,841,9±2,2398,0±11,0
NP91,0±4,648,5±2,9402,0±10,0
Hypoestrogenic stateSource160,0±6,2*was 124.9±5,5*385,0±13,0
OH about 91.8±8,057,3±7,1*385,0±9,0
NP87,4±7,5*57,8±6,6397,0±8,0
Hypoestrogenic state + blend solutions of homeopathic dilutions of polyclonal rabbit antibodies to endothelial NOS man - C12, C30, C200Source158,5±15,0120,7±9,9377,9±18,0
ESV with AH103,4±10,960,3±5,1381,0±16,4
ANSV with NP119,6±12,3is 78.4±8,2379,9±15,0
* - p<0,05 in comparison with the group intact; ** - p<0,05 in comparison with the group with hypoestrogenism state

We calculated this ratio for each animal intact group and rats after modeling hypoestrogen-induced deficiency of nitric oxide and got the difference of this indicator is 2 times respectively to 0.8 in the intact and 2.1 in animals with hypoestrogenism state.

Thus, to further assess the impact of AH and TM when ASW and AS the us used this respect, as an indicator correction of endothelial dysfunction.

Add in drinkers with free access to drinking a mixture of solutions gomeopaticheskih dilutions of polyclonal rabbit antibodies to endothelial synthase nitric oxide - C12, C30, C200 (BD Transduction Labs, USA) did not lead to reduction of the initial values of AD (GARDEN - 158,5±15,0, DBP - 120,7±9.9 mm Hg) (table 1).

However, in this group, where the background of bilateral oophorectomy at least 6 weeks were administered a mixture of solutions gomeopaticheskih dilutions of polyclonal rabbit antibodies to endothelial synthase nitric oxide person - C12, C30, C200 QED was 1.1, which was significantly lower than in the group with hypoestrogenism state.

Table 2
Indicators that reflect the correction hypoestrogen-induced endothelial dysfunction in the background of bilateral oophorectomy mixture solutions gomeopaticheskih dilutions of polyclonal rabbit antibodies to endothelial synthase nitric oxide person - C12, C30, C200.
Groups of animalsFunctional testsThe increase in the incidence of vascular response to Srad (mm Hg)The vascular reaction time (sec) The area of the vascular response (used)QED, the river.
units
The intactOH56,7±4,140,5±2,61673,6±132,40,8±
0,1
NP60,0±4,858,3±2,91338,1±121, 1million
Hypoestrogenic stateOH67,8±7,3*30,0±5,4*1022,5±131*2,1±
0,2*
NP79,2±8,8*46,0±4,5*2157,3±167*
Hypoestrogenic state + blend solutions of homeopathic dilutions of polyclonal antibodies to endothelial NOS man - C12, C30, C200OH65,1±5,8*61,9±4,3**2015,0±240,7**1,1±
0,1**
NP50,5±2,9**82,0±2,4**2065,6±116,9*
* - p<0,05 in comparison with the group intact, ** - p<0,05 in comparison with the group with hypoestrogenism state

Thus, the obtained results allow to conclude the correction hypoestrogen-induced endothelial amid bilateral oophorectomy mixture solutions gomeopaticheskih dilutions of polyclonal rabbit antibodies to endothelial synthase nitric oxide person - C12, C30, C200, reducing QED to the level of that of intact animals.

The method for correcting hypoestrogen-induced endothelial dysfunction, characterized in that in the experiment the females of Wistar rats for 6 weeks after oophorectomy daily 1 time per day administered in addition drinkers to drink a mixture of solutions of homeopathic dilutions of polyclonal rabbit antibodies to endothelial synthase nitric oxide person - C12, C30, C200.



 

Same patents:

FIELD: medicine.

SUBSTANCE: for tissue ischemia correction, in the reduced blood circulation environment an isolated pedicle skin flap is simulated in a laboratory animal. On the first, third and fifth experimental days, recombinant erythropoietin 50 IU/kg is injected subcutaneously.

EFFECT: method provides correction of the survival rate values of ischemic tissue of an isolated skin flap with a greater area of healthy tissue in 1,5 times in comparison with control animals, including due to the effective doses developed for such experiment and regiment of the drug.

1 tbl

FIELD: medicine.

SUBSTANCE: for the purpose of hypoestrogen-induced endothelial dysfunction correction in white female Wistar rats, hypoestrogen-induced endothelial dysfunction is simulated by bilateral ovariectomy. The dysfunction correction is ensured by daily intragastric introduction of enalapril 0.5 mg/kg for 6 weeks following the ovariectomy. The mixed solutions of homoeopathic dilutions of polyclonal rabbit C12, C30, C200 antibodies to human endothelial nitrogen oxide synthase are also introduced. The specified mixture is added to drinking bowls once a day.

EFFECT: method provides effective correction with reducing an endothelial dysfunction coefficient in females to the level observed in intact animals ensured by the effect on various developmental mechanisms of this dysfunction in hypooestrogenic conditions.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: endothelial dysfunction is ensured by intragastric introduction to a laboratory animal of the NO-synthase inhibitor - N-nitro-L-arginine of methyl ester (L-NAME) 25 mg/kg daily for 7 days. The endothelial dysfunction correction is ensured by intragastric introduction of atorvastatin 2.2 mg/kg and intragastric introduction of resveratrol 2 mg/kg once a day.

EFFECT: effective action of the combination of two specified preparations on vascular endothelium function.

1 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: for content change of lipid peroxidation products in laboratory rats caused by simultaneous or selective excitation of peripheral muscarine-sensitive and nicotine-sensitive structures (M- and N-cholinoceptive structures) of a plasmatic cell membrane, anticholinesterase accumulation mechanisms of endogenous acetylcholine in tissues are used. 30 minutes prior to the introduction of proserin, the rats are prescribed with: benzohexonium for activation of M-cholinoceptive structures only; methacin and atropine for activation of N-cholinoceptive structures only; proserin only is required for simultaneous excitation of peripheric M- and N-cholinoceptive structures. The experimental animals are placed in an environmental camera for cooling.

EFFECT: method allows changing the content of lipid peroxidation products in laboratory rats caused by simultaneous or selective excitation of peripheral M- and N-cholinoceptive structures of the plasmatic cell membrane with using anticholinesterase accumulation mechanisms of endogenous acetylcholine in tissues in the cold-loaded environment.

4 tbl

FIELD: medicine.

SUBSTANCE: modelling a myocardial infraction is followed by intravenous introduction of the immune corrector tamerite 3 mg/kg in an animal every days for seven days. The histological results of the myocardial tissue presented after the first, third and seventh days show the sufficiency and efficacy of the therapy.

EFFECT: effective therapy of the acute myocardial infraction ensured by reducing the intensity of an acute inflammatory reaction, providing faster granulation tissue formation.

2 tbl

FIELD: medicine.

SUBSTANCE: drug-free correction of structure functional brain dysfunction caused by severe hypoxia/ischemia is ensured by placing a model in 24 hours after severe hypoxia in a pressure chamber and hypoxic post-conditioning at atmospheric pressure 360 mm Hg for 2 hours every 24 hours for three days.

EFFECT: method extends the range of products for studying rehabilitation capabilities after hypoxia causing brain dysfunction.

2 dwg

FIELD: medicine.

SUBSTANCE: modelling a myocardial infraction is followed in a rat is followed by intravenous introduction of the immune corrector tamerite 3 mg/kg. The preparation is injected daily for seven days. The histological results of the myocardial tissue presented after the first, third and seventh days show the sufficiency and efficacy of the therapy.

EFFECT: effective therapy of the acute myocardial infraction with high possibility of cure ensured by reduced manifestations of systemic inflammation response syndrome, faster granulation tissue formation and necrotic zone replacement by cicatricial tissue.

FIELD: medicine.

SUBSTANCE: hypoestrogen-induced endothelial dysfunction correction in white female Wistar rats, hypoestrogen-induced endothelial dysfunction is simulated by bilateral ovariectomy. The dysfunction correction is ensured by daily intragastric introduction of lozartan 6 mg/kg and daily introduction of mixed solutions of homoeopathic dilutions of polyclonal rabbit C12, C30, C200 antibodies to human endothelial nitrogen oxide synthase once a day added to drinking bowls.

EFFECT: method provides effective correction with reducing an endothelial dysfunction coefficient in females to the level observed in intact animals ensured by the effect on various developmental mechanisms of this dysfunction in hypoestrogenic conditions.

1 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: reservatrol efficacy is studied in female Wistar rats with simulated osteoporosis by bilateral ovariectomy. For osteoporosis correction, reservatrol is administered in animal intraperitoneally for eight weeks after ovariectomy daily once a day in single dose 2 mg/kg. Osteoprotective action of reservatrol is estimated by a bone tissue microcirculation level and width of trabeculas of bone.

EFFECT: improved blood circulation and microarchitectonics of bone tissue in hypoestrogenic condition.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: efficacy is studied in female Wistar rats. Osteoporosis is simulated by bilateral ovariectomy. Osteoporosis is corrected by intraperitoneal introduction of reservatrol 2 mg/kg and intragastric introduction of enalapril 0.5 mg/kg daily once a day for eight weeks after ovariectomy. Osteoprotective action of reservatrol combined with enalapril is estimated by a bone tissue microcirculation level and width of trabeculas of bone.

EFFECT: improved blood circulation and microarchitectonics of bone tissue in hypoestrogen condition.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: for the purpose of hypoestrogen-induced endothelial dysfunction correction in white female Wistar rats, hypoestrogen-induced endothelial dysfunction is simulated by bilateral ovariectomy. The dysfunction correction is ensured by daily intragastric introduction of enalapril 0.5 mg/kg for 6 weeks following the ovariectomy. The mixed solutions of homoeopathic dilutions of polyclonal rabbit C12, C30, C200 antibodies to human endothelial nitrogen oxide synthase are also introduced. The specified mixture is added to drinking bowls once a day.

EFFECT: method provides effective correction with reducing an endothelial dysfunction coefficient in females to the level observed in intact animals ensured by the effect on various developmental mechanisms of this dysfunction in hypooestrogenic conditions.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: hypoestrogen-induced endothelial dysfunction correction in white female Wistar rats, hypoestrogen-induced endothelial dysfunction is simulated by bilateral ovariectomy. The dysfunction correction is ensured by daily intragastric introduction of lozartan 6 mg/kg and daily introduction of mixed solutions of homoeopathic dilutions of polyclonal rabbit C12, C30, C200 antibodies to human endothelial nitrogen oxide synthase once a day added to drinking bowls.

EFFECT: method provides effective correction with reducing an endothelial dysfunction coefficient in females to the level observed in intact animals ensured by the effect on various developmental mechanisms of this dysfunction in hypoestrogenic conditions.

1 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to Trecresan application for improving heart haemodynamics and reduction of metabolic disorders in treating the patients suffering arterial hypertension and obesity, and also its combinations with ATE inhibitors.

EFFECT: higher clinical effectiveness.

3 cl, 3 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula (I) given below or pharmaceutically acceptable salts thereof:

[where: each of X, Y, Z and W independently denotes a methane group which optionally contains substitutes selected from a group of substitutes α, or a nitrogen atom (except when all elements X, Y, Z and W denote a methane group which optionally contain substitutes selected from the group of substitutes α); A denotes -(C(R3)(R4))m1-; B denotes -O-; D denotes -C(O)-; m1 equals 0; Q denotes a methane group or a nitrogen atom; R denotes a group of formula (II)

, where R6 denotes a lower alkyl group; R7 and R8, together with the nitrogen atom with which they are bonded, form a 5-6-member nitrogen-containing aliphatic heterocyclic group; and where the group of substitutes α includes the following substitutes. Group of substitutes α: halogen atom, hydroxyl group, lower alkyl group, alkoxyl group (said group can be substituted with a cycloalkyl group), amino group, mono- or disubstituted lower alkylamino group, aryl group (said group can be substituted with a halogen atom, a -SO2CH3 group), aryloxy group (said group can be substituted with a halogen atom), heteroaryl group, where 'heteroaryl group' denotes a 5- or 6-member monocyclic saturated or unsaturated group containing 1-2 heteroatoms selected from an oxygen atom or a nitrogen atom (said group can be substituted with an alkoxyl group, alkyl group). The invention also relates to a histamine 3 receptor antagonist, histamine 3 receptor inverse agonist, a prophylactic or medicinal agent, as well as a pharmaceutical composition.

EFFECT: obtaining novel biologically active compounds having histamine H3 receptor antagonist or inverse agonist action.

15 cl, 57 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to indole-3-yl-carbonyl-spiro-piperidine derivatives which have an effect of Vla-receptor antagonists and are presented by Formula I: where a tail spiropiperidine group A and residual R1, R2 and R3 are such as specified in the patent claim.

EFFECT: higher efficiency of applying the compounds in drugs effective in dysmenorrhea, hypertension, chronic heart failure, inadequate vasopressin secretion, hepatic cirrhosis, nephrotic syndrome, obsessive-compulsive disorder, anxious and depressive disorders.

22 cl, 42 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiology, hematology, and can be applied for reduction of spontaneous erythrocyte aggregation in case of arterial hypertension with metabolic syndrome. For this purpose administered are dosed static and dynamic physical activity, daily swimming for not less than 40 min. per day in the middle of the day, as well as lisinopril in dose 10 mg 1 time per day in the morning and methformin 500 mg 2 times per day. Physical activity includes morning hygienic gymnastics, therapeutic-preventive gymnastics and divided physical exercises during the day. Treatment course is 2 months.

EFFECT: combination of treatment methods makes it possible to reduce spontaneous erythrocyte aggregation, which assists prevention of thrombotic complications in said category of patients.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to haematology and cardiology, and concerns reducing spontaneous erythrocyte aggregation (SEA) in arterial hypertension with impaired glucose tolerance.. That is ensured by the integrated treatment that involves the administration of lisinopril 10 mg once a day in the morning and metformin 500 mg twice a day for 2 months, as well as graduated static and dynamic physical activity, including daily swimming for at least 30 minutes a day.

EFFECT: complex of drug-induced and drug-free modalities ensure reducing the SEA for 2 months that in turn promotes normalised blood rheology and reduced risk of thrombotic complications in the case patients.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to gerontology and cardiology and can be used for reduction of pathologically increased biological age (BA) in patients with arterial hypertension (AH) with abdominal obesity (FO) and dyslipidemia. Essence of claimed method lies in the following: to patients administered is complex, that includes hypocaloric diet, calculated in kcal by formula: for women: 18-30 years old - (0.0621 × body weight, kg + 2.0357) × 240; 31-60 years old - (0.0342 × body weight, kg + 3.5377) × 240; over 60 years old - (0.0377 × body weight, kg + 2.7545) × 240; for men: 18-30 years old- (0.0630 × body weight, kg+ 2.8957) × 240; 31-60 years old - (0.0484 × body weight, kg + 3.6534) × 240; over 60 years old - (0.049 × body weight, kg + 2.4587) × 240. Also administered are rationally dosed static and dynamic physical loadings, including morning hygienic gymnastics, preventive medical gymnastics, fractional physical exercises during the day, daily swimming in swimming pool for not less than 60 minutes per day. Also introduced are medications simvastatin 10 mg 1 time before going to bed after meal and lisinopril 10 mg 1 time per day in the morning for not less than 7 weeks.

EFFECT: invention combines application of all components of complex allows to normalise BA within 7 weeks of treatment.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gerontology and cardiology, and concerns biological age reduction in arterial hypertension combined with abdominal obesity. That is ensured by the integrated treatment including a low-calorie diet, reasonable graduated static and dynamic physical activity, daily swimming in a pool for at least 30 minutes, and the introduction of lisinopril in dosage 10 mg once a day in the morning and metformin in dosage 500 mg twice a day for the therapeutic course of 7 weeks.

EFFECT: complex of drug-induced and drug-free therapy combined with empirically prescribed treatment length provides biological age reduction in the case patients estimated by the relation of electronegative cells to total count in a buccal epithelium scrape due to normalised DNA repair and chromosome fragility level.

2 ex

FIELD: medicine.

SUBSTANCE: invention belongs to medicine, notably to haematology and cardiology and refers to reduction of spontaneous erythrocytes aggregation in patients with arterial hypertension. This is ensured by the integrated treatment including graduated static and dynamic physical loads, including daily swimming for at least 20 minutes in the middle of the day, daily, and administration of lisinopril 10 mg once a day in the morning and amlodipine 10 mg once a day in the morning.

EFFECT: combined drug-free and drug therapies during empirically fitted period ensure effective reduction of spontaneous aggregation of erythrocytes, which, in turn, allows to improve blood's rheological properties and reduce risk of thrombotic complications in patients with arterial hypertension.

2 ex

FIELD: medicine.

SUBSTANCE: for the purpose of hypoestrogen-induced endothelial dysfunction correction in white female Wistar rats, hypoestrogen-induced endothelial dysfunction is simulated by bilateral ovariectomy. The dysfunction correction is ensured by daily intragastric introduction of enalapril 0.5 mg/kg for 6 weeks following the ovariectomy. The mixed solutions of homoeopathic dilutions of polyclonal rabbit C12, C30, C200 antibodies to human endothelial nitrogen oxide synthase are also introduced. The specified mixture is added to drinking bowls once a day.

EFFECT: method provides effective correction with reducing an endothelial dysfunction coefficient in females to the level observed in intact animals ensured by the effect on various developmental mechanisms of this dysfunction in hypooestrogenic conditions.

2 tbl, 1 ex

Up!